Trials / Completed
CompletedNCT06313528
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 85 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3437943 | Administered SC |
| OTHER | Placebo | Administered SC |
Timeline
- Start date
- 2024-03-20
- Primary completion
- 2025-08-26
- Completion
- 2025-08-26
- First posted
- 2024-03-15
- Last updated
- 2025-09-23
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06313528. Inclusion in this directory is not an endorsement.